• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Covaxin receives GMP certificate from Hungarian authorities

expresspharmaAugust 06, 2021

Tag: Covaxin , GMP , Bharat Biotech

Covaxin has received a certificate of Good Manufacturing Practice (GMP) compliance from the Hungarian authorities, Bharat Biotech said in a statement.

The approval received is from the National Institute of Pharmacy and Nutrition Hungary certifying the GMP for the manufacturing of Covaxin. The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorisations and certificates of the good manufacturing practice. Bharat Biotech intends to submit documentation for Emergency Use Authorisation (EUA) in several additional countries worldwide, it added.

Previous:Product List of Nanjing Foreign Economic & Trade Development Co., Ltd. - APIs

Next:LANXESS completes acquisition of Emerald Kalama Chemical

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Covaxin receives GMP certificate from Hungarian authorities | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

pGmpC•NH4 salt

pGmpC•NH4 salt
99% up GMP DMF Anisodamine powder 55869-99-3

99% up GMP DMF Anisodamine powder 55869-99-3
99% up GMP DMF Nandrolone phenylpropionate 62-90-8

99% up GMP DMF Nandrolone phenylpropionate 62-90-8
99% up GMP DMF Sitafloxacin Hydrate 163253-35-8

99% up GMP DMF Sitafloxacin Hydrate 163253-35-8
99% up GMP DMF Bromhexine hydrochloride/ Bromhexine HCL 611-75-699% up GMP DMF Bromhexine hydroc

99% up GMP DMF Bromhexine hydrochloride/ Bromhexine HCL 611-75-699% up GMP DMF Bromhexine hydroc
99% up GMP DMF Troxipide 30751-05-4

99% up GMP DMF Troxipide 30751-05-4
99% up by HPLC USP GMP DMF Fulvestrant 129453-61-8

99% up by HPLC USP GMP DMF Fulvestrant 129453-61-8
carbamazepine USP/BP GMP Made in China

carbamazepine USP/BP GMP Made in China
GMP peptide production

GMP peptide production
99% up GMP DMF Amoxicillin/ Amoxicillin trihydrate 26787-78-0

99% up GMP DMF Amoxicillin/ Amoxicillin trihydrate 26787-78-0

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service